Sanford Health has partnered with Chronix Biomedical in a new cancer study. The basis of the study is the ability to map out whole genomes of cancer cells. The big question: can this ability be used to predict how cancer patients will respond to different therapies? Dr. John Lee of Sanford Health joined the program to discuss the study, along with Chronix Biomedical CEO Dr. Howard Urnovitz and Professor Ekkehard Schutz, Chief Techonology Officer of Chronix.
Pilot Study Seeks Ways To Predict Best Cancer Treatments
By Jackie Hendry • Jun 10, 2014